In May 2019, Stephen P. MacMillan, the Chairman, President and Chief Executive Officer of Hologic, Inc. (the “Company”) entered into a stock trading plan (the “Plan”) in accordance with the guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and the Company’s policies with respect to insider trading and stock ownership. The Plan covers an option to purchase 223,996 shares and an option to purchase 639,988 shares, both of which were granted to Mr. MacMillan when he joined the Company in December 2013. These options are scheduled to expire next year on December 6, 2020.

Rule 10b5-1 permits corporate officers, directors and others to adopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. Using these plans, insiders may gradually diversify their investment portfolios and spread stock trades over a period of time regardless of any material, non-public information they may receive after adopting their plans. In accordance with Rule 10b5-1, Mr. McMillan will have no discretion over the transactions effected under the Plan.

to the Plan, Mr. MacMillan will exercise these expiring options to purchase shares on specified dates in each of the next four quarters, subject to the satisfaction of certain conditions contained in the Plan. A portion of the shares he purchases through the exercises will be sold, and a portion of the shares will be retained. As a result of exercising the options and retaining a portion of the shares purchased, Mr. MacMillan will add to the significant ownership position he already has in Hologic, which includes shares he purchased in the open market in 2014.

Mr. MacMillan has not sold any shares of Hologic since joining the Company. Including outstanding shares and vested but deferred restricted stock units, he currently owns over 1.4 million shares, which would make him one of the Company’s 25 largest shareholders.

Any transactions under the Plan will be disclosed publicly through Form 4 filings with the Securities and Exchange Commission when due. Except as may be required by law, Hologic does not undertake to report modifications or terminations of the Plan or entry into any stock trading plans by other officers or directors of the Company.

About HOLOGIC, INC. (NASDAQ:HOLX)

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.